Clinical Trial Update: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) [Phase 1]

View source ↗

Summary

This Phase 1 pharmacokinetics study evaluated the effect of rifampin on the pharmacokinetics of vemurafenib (Zelboraf) in patients with malignant melanoma; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• RIFAMPIN (RIFAMPIN)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma, Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2016-12-15